Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aeglea Biothera (NQ: AGLE )

6.490 USD -0.070 (-1.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 49,085
Open 6.600
Bid (Size) 6.480 (10)
Ask (Size) 6.490 (20)
Prev. Close 6.560
Today's Range 6.450 - 6.680
52wk Range 6.150 - 9.900
Shares Outstanding 49,023,640
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today... 
From PR Newswire
Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Me
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today... 
From PR Newswire

Performance

YTD
-24.18%
-24.18%
1 Month
-17.11%
-17.11%
3 Month
-21.90%
-21.90%
6 Month
-15.05%
-15.05%
1 Year
-12.00%
-12.00%

More News

Read More
Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer
From PR Newswire
Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria
From PR Newswire
Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors
From PR Newswire
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
From PR Newswire
Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency
From PR Newswire
Asher Bio Appoints Leading Experts in Immunology, Oncology and Protein Therapeutics to its Scientific Advisory Board
From Business Wire News Releases
Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency
From PR Newswire
Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
From PR Newswire
Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.